A rational approach to cancer therapy by Gorringe, Kylie L & Campbell, Ian G
Genome B Bi io ol lo og gy y   2008, 9 9: :306
Meeting report
A A   r ra at ti io on na al l   a ap pp pr ro oa ac ch h   t to o   c ca an nc ce er r   t th he er ra ap py y
Kylie L Gorringe* and Ian G Campbell*†
Addresses: *VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. 
†Department of Pathology, University of Melbourne, Melbourne, Victoria 8006, Australia.
Correspondence: Ian G Campbell. Email: ian.campbell@petermac.org
Published: 7 May 2008
Genome B Bi io ol lo og gy y 2008, 9 9: :306 (doi:10.1186/gb-2008-9-5-306)
The electronic version of this article is the complete one and can be
found online at http://genomebiology.com/2008/9/5/306
© 2008 BioMed Central Ltd 
A report on the 20th Annual Lorne Cancer Conference,
Lorne, Australia, 14-16 February 2008.
Targeted molecular therapy for cancer is becoming a holy
grail for researchers. The identification and characterization
of cancer genes is the first step towards developing such
therapeutics, and high-throughput technologies are increas-
ingly being used to identify these genes, elucidate their
function and identify potential drug molecules that target
them. At all levels of this process, a deep understanding of
the molecular pathways involved is crucial to the successful
development of a new therapeutic. In particular,
combinations of therapies that each target aspects of the
same or interacting pathways offer possibilities for synergy,
reducing overall drug exposure and side effects for the
patient. These themes were well covered at this years’s Lorne
cancer conference.
H Hi ig gh h- -t th hr ro ou ug gh hp pu ut t   t te ec ch hn no ol lo og gi ie es s
The impact of high-throughput technologies on cancer
research was electrifyingly demonstrated by Mike Stratton
(Wellcome Trust Sanger Centre, Cambridge, UK), who
showed how next generation massively parallel sequencing
technologies can be used to determine the fine structure of
chromosomal rearrangements. He described published work
on the identification of rearrangement breakpoints in cancer
cells. This involved the sequencing of large numbers of
bacterial artificial chromosome clones with mismatched end
sequences, each clone representing an individual rearrange-
ment. The incredible complexity of these rearrangements
could not have been appreciated without the level of detail
that deep sequencing can provide, and led Stratton to
describe a new model for the life history of these “deranged
architectures” containing “genomic shards”. He proposed
that these latter small sequences, which range from 60 bp to
a few kilobases, could arise through degradation of double-
strand breaks (DSBs) and that they are captured by the
repair machinery in an attempt to heal other DSBs,
primarily through non-homologous end joining. This model
is in contrast to the ‘breakage-fusion-bridge’ cycle previously
proposed for gene amplification. Stratton also described
some new work using the Genome Analyzer® system from
Illumina, which enables not only short sequence reads but
also the measurement of copy number based on the
representation of each sequence within the population. The
copy-number output Stratton presented exceeded even the
level of resolution obtainable by the Affymetrix SNP 6.0
array, which with over 1.8 million probes is currently the
leader in high-resolution copy-number mapping. The two
outputs - sequence and copy number - could then be
combined to look at the structure of gene amplicons, for
example, to identify fusion genes.
An alternative method of identifying cancer genes was
described by Anton Berns (Netherlands Cancer Institute,
Amsterdam, the Netherlands). In this approach, integration
of viral sequences into the mouse genome initiated tumor
growth, leading to identification of the gene responsible
through transposon tagging of the insertion site. His group
has characterized more than 1,000 mouse lymphomas by
sequencing each of the 20 insertion sites per tumor, more
than half of which lay within genes. Interestingly, the
frequency of detection of a particular insertion site depended
on the genetic background of the mouse, which helped link
the identified gene to a biochemical pathway. For example,
tumors arising in a p53-knockout background were more
likely to have insertions in the gene for cyclin D3, Ccnd3,
than were tumors on a wild-type background. Of the
common genes identified in the screen, only 15% overlapped
with known human cancer genes such as the retinoblastoma
gene  RB1, suggesting that the remainder might represent
novel targets of amplifications and deletions.Characterizing genes and pathway interactions is clearly a
crucial step in elucidating oncogenesis, and high-throughput
analysis of pathways in model organisms offers one way of
doing this. Norbert Perrimon (Harvard Medical School,
Boston, USA) described a remarkable resource for high-
throughput screens in Drosophila. The Drosophila RNAi
Screening Center (DRSC) is building libraries of RNAi and
cDNA clones to ultimately cover the entire Drosophila
genome. More than 70 screens using this resource have been
carried out, 28 of which have been published. Perrimon
described screens using impressive confocal microsopic
readouts with semi-automated fluorescent methods for
detecting and scoring morphological features of the cells
under study in order to identify genes and pathways that
control cell shape, for example.
U Un nd de er rs st ta an nd di in ng g   o of f   p pa at th hw wa ay ys s   l le ea ad di in ng g   t to o   t ta ar rg ge et te ed d   a an nd d
c co om mb bi in na at ti io on n   t th he er ra ap pi ie es s
How biochemical pathways can be used to find new
therapeutics was illustrated by David Lane (University of
Dundee, UK), who described a screen aimed at identifying
small molecules that would activate p53. Tumors with wild-
type  p53 but perturbation of the pathway through
inactivation of CDKN2A inactivation or overexpression of
MDM2 would be specifically targeted by these drugs to
reactivate the p53 pathway. Like nutlin (a cis-imidazole),
these drugs sensitize the tumors to the effects of other
therapies in combination, while reducing side effects on
normal cells. The screen, encompassing 34,000 different
molecules, utilized a reporter construct to detect p53 trans-
cription factor activity. The 33 reproducible ‘hits’ were then
used in a yeast genetic screen to identify the target genes.
The small-molecule screen thus not only found new
potential therapeutic agents, but also new p53 pathway
genes, encoding the sirtuins, which function as deacetylases.
Lane also described screens using small concentrations of
each drug to identify those combinations that provide
synergism, thus increasing selectivity and potency as well as
reducing genotoxicity and side effects.
Drug combinations, this time targeting the apoptotic pathway,
were the focus of a talk by Suzanne Cory (Walter and Eliza
Hall Institute, Melbourne, Australia). The chemotherapeutic
cyclophosphamide acts through apoptotic pathways that
tumors may often be resistant to. Cory described how when
combined with cyclophosphamide, the BH3 mimetic
ABT-737 has been shown to increase survival and decrease
side effects in a mouse model compared to cyclophos-
phamide alone. Similarly, Mike Bishop (University of
California, San Francisco, USA) who gave this year’s Ashley
Dunn Oration, described several mouse models in which
drug combinations and targeted molecular therapies result
in improved survival. His optimistic and warmly received
talk covered the targeting of several oncogenes, including
MYC and the PML-RAR fusion gene. He described the drug
VX-680, which kills only MYC-expressing cells through a
combination of apoptosis and delayed toxicity via auto-
phagy. Interestingly, autophagy continued to occur even
when the drug was removed after the initial treatment,
thereby decreasing side effects.
One of the looming unresolved issues in targeted thera-
peutics is the evolution of drug resistance. In a stand-out
talk, Alan Ashworth (Breakthrough Breast Cancer Research
Centre, London, UK) described the rational identification of
PARP inhibitors (PIs) that specifically target tumors with
defective DNA repair pathways, such as BRCA1- and
BRCA2-deficient tumours. This class of compounds was
identified through a synthetic lethality screen, in which the
cell, already sensitized to DNA damage by loss of BRCA1/2,
is overwhelmed by the combination of a chemotherapeutic
agent that causes DNA damage and a compound that
prevents DNA repair through an alternative pathway, in this
case base excision repair. This combination results in the
cells sustaining fatal genomic instability. In elegant work
that has recently been published, Ashworth’s group
proactively looked for mechanisms of PI resistance in the
CAPAN-1 (BRCA2 null) cell line by treating the cells with the
drug and identifying the genetic alterations in resistant
clones. Fascinatingly, the resistance was found to be
mediated by deletions within BRCA2 that removed the
original germline frameshift mutation, restoring the coding
sequence to the correct frame with an in-frame fusion that,
while still missing parts of the protein, appears to have
sufficient function to restore DNA repair and enable
resistance. Similar deletions were identified in ovarian
cancer patients with resistance to carboplatin. Ashworth also
addressed a question that frequently arises when discussing
resistance to therapies - whether resistance arises through a
conventional ‘Darwinian’ selective mechanism or by some
type of de novo response to the presence of the drug.
Ashworth supported the more logical Darwinian mecha-
nism, by which resistance existing in a small proportion of
tumor cells gives them a selective advantage upon treatment,
allowing the clone containing the mutation to expand. At
present there is no known mechanism for a resistance-
enabling mutation to arise de novo in response to drug
treatment. The Darwinian mechanism still remains to be
tested in the context of drug resistance in cancer cells, but
the high-throughput technologies now available could
provide the means for a definitive experiment.
Although the development of targeted therapies has been
slow so far, their promise is incontrovertible. Intelligent use
of the high-throughput tools now available is accelerating
the pace of discovery such that rational drug design will
become the rule, rather than the exception.
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